Mallinckrodt to buy Sucampo Pharmaceuticals for about $1.2 billion: Reuters

Mallinckrodt Plc (MNK.N) said on Tuesday it would buy Sucampo Pharmaceuticals Inc (SCMP.O) in a deal valued at about $1.2 billion to gain access to its constipation drug, Amitiza.

Mallinckrodt said it expects the deal to add to its 2018 adjusted earnings per share by at least 30 cents.